Marc MD - Edgewise Therapeutics Chief Officer
| EWTX Stock | USD 20.34 0.82 4.20% |
Executive
Marc MD is Chief Officer of Edgewise Therapeutics
| Age | 67 |
| Address | 1715 38th Street, Boulder, CO, United States, 80301 |
| Phone | 720 262 7002 |
| Web | https://www.edgewisetx.com |
Edgewise Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2022) % which means that it has lost $0.2022 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.301) %, meaning that it created substantial loss on money invested by shareholders. Edgewise Therapeutics' management efficiency ratios could be used to measure how well Edgewise Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.31 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, Edgewise Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 9 M in 2024, whereas Total Assets are likely to drop slightly above 252.6 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
| Kianoush Motesharei | Madrigal Pharmaceuticals | ||
| Candice Masse | Elevation Oncology | N/A | |
| PharmD MBA | Madrigal Pharmaceuticals | N/A | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
| Scott Gottesman | AVROBIO | N/A | |
| Steven CPA | Ginkgo Bioworks Holdings | N/A | |
| Joshua Dunn | Ginkgo Bioworks Holdings | N/A | |
| Karen Tepichin | Ginkgo Bioworks Holdings | N/A | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| Anna Wagner | Ginkgo Bioworks Holdings | N/A | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Kevin CPA | Enveric Biosciences | 60 | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| Steven JD | AVROBIO | 62 | |
| Robert Yang | Elevation Oncology | N/A | |
| Ronald Filippo | Madrigal Pharmaceuticals | N/A | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.2 |
Edgewise Therapeutics Leadership Team
Elected by the shareholders, the Edgewise Therapeutics' board of directors comprises two types of representatives: Edgewise Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edgewise. The board's role is to monitor Edgewise Therapeutics' management team and ensure that shareholders' interests are well served. Edgewise Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edgewise Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Koch, CEO President | ||
| Badreddin Edris, CoFounder Director | ||
| John Moore, General Counsel | ||
| Behrad Derakhshan, Chief Officer | ||
| Marc MD, Chief Officer | ||
| MD FACP, CoFounder Chairman | ||
| Alan Russell, Chief CoFounder | ||
| Michael Carruthers, Chief Officer |
Edgewise Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edgewise Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 1.58 B | ||||
| Shares Outstanding | 93.41 M | ||||
| Shares Owned By Insiders | 0.46 % | ||||
| Shares Owned By Institutions | 99.60 % | ||||
| Number Of Shares Shorted | 5.76 M | ||||
| Price To Earning | 3.45 X | ||||
| Price To Book | 4.78 X | ||||
| EBITDA | (112.62 M) |
Edgewise Therapeutics Investors Sentiment
The influence of Edgewise Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Edgewise. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Edgewise Therapeutics' public news can be used to forecast risks associated with an investment in Edgewise. The trend in average sentiment can be used to explain how an investor holding Edgewise can time the market purely based on public headlines and social activities around Edgewise Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Edgewise Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Edgewise Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Edgewise Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Edgewise Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Edgewise Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Edgewise Therapeutics' short interest history, or implied volatility extrapolated from Edgewise Therapeutics options trading.
Pair Trading with Edgewise Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edgewise Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edgewise Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Edgewise Stock
| 0.64 | HCWB | HCW Biologics | PairCorr |
| 0.52 | KTTA | Pasithea Therapeutics | PairCorr |
| 0.47 | IQV | IQVIA Holdings | PairCorr |
The ability to find closely correlated positions to Edgewise Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edgewise Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edgewise Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edgewise Therapeutics to buy it.
The correlation of Edgewise Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edgewise Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edgewise Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edgewise Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edgewise Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Edgewise Stock analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Edgewise Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edgewise Therapeutics. If investors know Edgewise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edgewise Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.57) | Return On Assets (0.20) | Return On Equity (0.30) |
The market value of Edgewise Therapeutics is measured differently than its book value, which is the value of Edgewise that is recorded on the company's balance sheet. Investors also form their own opinion of Edgewise Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Edgewise Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edgewise Therapeutics' market value can be influenced by many factors that don't directly affect Edgewise Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edgewise Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edgewise Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edgewise Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.